LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Ardent Health to Participate in March Investor Conferences

February 25, 2025 | Last Trade: US$11.78 0.33 -2.73

BRENTWOOD, Tenn. / Feb 25, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that members of the Company’s management team will participate in the following investor conferences:

  • Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, in Miami, Florida. Members of the management team will participate in a fireside chat discussion at 8 a.m. ET that same day.
  • KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025. Members of the management team will participate in a fireside chat discussion at 9 a.m. ET that same day.

A live audio webcast of these presentations will be available at the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com, and a replay will be available for 90 days using the same link.

In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations, at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,800 affiliated providers across six states. For more information, please visit www.ardenthealth.com.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page